Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > I have a new rabbit hole to go down
View:
Post by DJDawg on Jul 08, 2024 3:15pm

I have a new rabbit hole to go down

Given the information that comes out of TLT, one sometime has to do detective work around the news releases. I have new angle to digest. Bear with me. This may not make sense but I'll try.

June 6: News release about Rutherrin destroying lung cancer. Report says that all treated mice are still alive but that that is not the case for the xray only lung cancer mice.

June 13 - first news of PP for 10m. Email from M.P. Expected to close June 21 or 28?

June 19 - news release that one mouse still alive and apparently cured based on no tumour found.

Based on the time points above the experiment with the mice above was started around May 12.

If you look at the dates of above it is an interesting sequence. Some people may have thought that the mice lung cancer study was brand new information. However, the way the information related to this push of news releases and the announcement of the results of the mice treated is such that it was timed perfectly to give two updates, all centered around the public relations push for the new offering.

The timing is quite precise. Plus only 5 mice treated in each arm. I think that that suggests that TLT has done this experiment enough times that they know the results are reproducable. And can plan on them.

Plus treating on 5 and 5 mice is a very small sample. Most dont' work that predictably so you need to do bigger sample sizes. Doing with only 5 mice in each arm is an interesting risk as that is such a small sample.

Put another way, I think that they have done the lab mice study repeatedly before and have found such reproducable very good cancer benefit that RDW and Dr. Mandel set up a small mice experiment timed so that they could spin off some real time news releases in the pump for the offering.

The takeaway from this for me is that Rutherrin is not a gimmick that has only worked in one lab trial with only 5 mice. They have done it enough times that they know how the lab results will play out and can plan around it. It also tells me that they have had repeated practice attempts on dose finding in mice lung cancer so that they are much further along then just having done it for the first time in May June.

I'm not trying to play cheerleader for TLT but I love the science and think that the timing of all this hints at some great reproducable anticancer benefit for Rutherrin in lung cancer.



Comment by BlueFranky on Jul 08, 2024 3:38pm
Overwhelming and predictable results on a small phase one...On a life or death cancer  For which the greatest of urgency should be afforded? Could it be that we're setting ourselves up for one remaining trial on Lung ... Much like nmibc? Cuz that's where I think we're heading!
Comment by DJDawg on Jul 08, 2024 3:45pm
I don't know but my hunch is that GBM is the plan for next step. GBM is rapidly fatal with limited treatment options. If you set up a phase 1a in Toronto you would have no trouble getting patients and the turnaround time to show benefit would be a few months (acceptable benefit for GBM would be a drop in size of tumour about 1 cm in diameter). That wouldn't be hard to prove if it works ...more  
Comment by Eoganacht on Jul 08, 2024 4:12pm
I may be wrong, but the way I read the last MD&A Theralase plans to do a single adaptive Phase Ib/II which includes both GBM and NSCLC. Once Rutherrin®’s Maximum Tolerated Dose (“MTD”) and hence Human Equivalent Dose (“HED”) limits have been determined through Good Laboratory Practices (“GLP”) toxicology studies, Theralase®, subject to the required regulatory approvals, plans ...more  
Comment by stocksnbonds458 on Jul 08, 2024 8:35pm
DJDawg and Eoganacht, as always your insights and analysis are well regarded and appreciated. With respect to what you guys may consider "hunches" or "guesses" regarding future direction in clinical studies,  why not just call Roger and ask him? 
Comment by Alamir1111 on Jul 08, 2024 4:03pm
Plus treating on 5 and 5 mice is a very small sample. Most dont' work that predictably so you need to do bigger sample sizes. Doing with only 5 mice in each arm is an interesting risk as that is such a small sample. I agree that is a small sample maybe enrollment slowed  down or central pathology laboratory didn't do their job properly?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250